• Anton P Porsteinsson, Melanie A Keltz, and Jessica S Smith.
• University of Rochester School of Medicine & Dentistry Alzheimer's Disease Care, Research & Education Program (AD-CARE), 435 East Henrietta Road, Rochester, NY 14620, USA.
• Neurodegener Dis Manag. 2014 Jan 1; 4 (5): 345-9.

AbstractNeuropsychiatric symptoms (NPS) are common among individuals with Alzheimer's disease (AD), associated with excess morbidity and mortality, greater healthcare use, earlier institutionalization, and caregiver burden. Agitation presents as emotional distress, excessive psychomotor activity, aggressive behaviors, disruptive irritability and dishibition. There is an unmet need to find pharmacologic treatment for agitation in patients with AD that can be safely and effectively used as a concurrent treatment alongside psychosocial interventions. A recent, multicenter, randomized, placebo-controlled trial explored the efficacy of a 30-mg daily dose of citalopram for agitation in patients with AD and showed a significant decrease in agitation for citalopram compared with placebo. Both QTc prolongation and cognitive worsening, as measured by the Mini Mental State Examination, were observed in the citalopram group and present a concern to clinicians. Citalopram at a 20-mg daily dose should be considered as a possible first-line treatment in addition to psychosocial intervention.

18 keywords...

hide…